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Introduction Antiretroviral therapy (ART), combines three or more anti-HIV-1 compounds and has proven to be effective in reducing viral load and HIV-1 related mortality (Pomerantz and Horn, 2003) . Zidovudine (3'-azido-3'-deoxythymidine , AZT), a nucleoside reverse transcriptase inhibitor (NRTI), was the first drug to be approved for the treatment of HIV-1 (Ezzell, 1987) . A number of NRTIs, such as emtricitabine (FTC), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), didanosine (ddI), tenofovir and abacavir (ABC) have since been approved. Standard combination therapy of HIV-1 infection often includes a dual NRTI 'backbone' with the addition of a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor (Werber, 2003) . Both ABC and AZT ( Figure 1 ) are frequent components of combination therapies that have proved to be effective for HIV-1 treatment, for example, indinavir + AZT/d4T + 3TC (Baker, 1997) and (abacavir + 3TC + AZT (Trizivir)) (Kessler, 2005) .
HIV-1 has been shown to penetrate the central nervous system (CNS) and replicate in brain macrophages and microglia (Kure et al., 1991; Bagasra et al., 1996) . Moreover, the CNS provides a sanctuary for the virus in the body due to insufficient antiretroviral drug delivery through the blood-brain barrier (BBB) (Pialoux et al., 1997) . Numerous studies have implicated efflux transport proteins in the BBB in limiting the CNS distribution of some therapeutic agents (Polli et al., 2003; Park and Sinko, 2005) . A number of drug efflux transporters have been identified and localized at the BBB, such as P-gp (Cordon-Cardo et al., 1990) , MRPs (Mohri et al., 2000) , OATPs (Pizzagalli et al., 2002) and BCRP/ABCG2 (Cooray et al., 2002; Hori et al., 2004) .
ABCG2/ BCRP is a relatively new member of the ATP-binding cassette transporter superfamily discovered in mitoxantrone-resistant cell lines that do not overexpress P-gp or the MRPs (Doyle et al., 1998) . BCRP has been localized in the plasma membrane (Minderman et al., 2002) of cells forming various tissue barriers like the small intestines, colon, bile canaliculi, placental syncytiotrophoblast and the BBB (Jonker et al., 2000; Cooray et al., 2002) . The expression of rat Bcrp1 cDNA was found to be approximately 7-fold higher in the brain capillary fraction when compared to the small intestine in rats, suggesting that this efflux protein may play a significant role in limiting brain distribution of its substrates (Hori et al., 2004) . The cellular and tissue distribution and efflux transport function of BCRP may be critical in the absorption, distribution, and efficacy of several anti-HIV1 agents, and their passage across the BBB and blood-placental barrier into protected sites.
The CNS exposure of AZT and other NRTIs has been found to be much lower in the brain when compared to the blood concentrations. Active efflux transport out of the CNS is speculated to be a predominant mechanism limiting these NRTIs distribution to the CNS (Sawchuk and Yang, 1999) . ABC has also been shown to have lower CNS exposure when compared to plasma or whole blood in rats, guinea pigs, monkeys and humans. (Daluge et al., 1997; McDowell et al., 1999; Thomas et al., 2001) . Currently, there are no reports that identify efflux transport proteins that may be involved in the absorption and distribution of ABC. Recent studies have shown that AZT has decreased cytotoxicity and anti-HIV1 activity in CD4 + Tcells that overexpress the wild-type and mutant variants of the efflux transporter BCRP (Wang et al., 2003) .
These BCRP overexpressing cell lines were also shown to have a reduced accumulation of AZT which was reversed by the BCRP inhibitor, fumitremorgin C (Wang et al., 2003; Wang et al., 2004) . However, the involvement of BCRP in the polarized transport of AZT is yet to be reported and there are no reports regarding the interaction of ABC and BCRP or other efflux transporters.
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The objective of this study was to characterize the interaction of ABC and AZT with murine Bcrp1, which is homologous to human BCRP. An in vitro MDCKII cell model transfected with Abcg2/Bcrp1 was used to assess this interaction with ABC and AZT. If BCRP is shown to be an important transporter of ABC and AZT at critical barriers, then modulation of BCRP-mediated efflux transport of ABC and AZT may lead to efficacious treatment and improved availability to specific sites of action, such as the CNS sanctuary and the target lymphocytes.
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Cell culture
MDCK-II wild type and Bcrp1-transfected cell lines (Jonker et al., 2000) were kindly provided by Dr.
Alfred H. Schinkel, The Netherlands Cancer Institute. Cells used for all our experiments were between passages 5-15. The cells were cultured in DMEM (Mediatech, Inc., Herndon, VA) supplemented with 10% fetal bovine serum (SeraCare Life Sciences, Inc., Oceanside, CA), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Sigma-Aldrich, Inc., Saint Louis, MO). All other cell culture materials were obtained from BD Biosciences (San Jose, CA).
Intracellular accumulation
The wild-type and Bcrp1-transfected cells were seeded at a density of 2 x 10 5 per well and were grown for 2 to 3 days on 12-well plates (TPP® tissue culture plates) to form confluent epithelial monolayers. For the experiment, the growth media was aspirated and the cells in each well were washed twice with 2 ml of assay buffer, followed by preincubation for 30 minutes with 1 ml of assay buffer. The accumulation experiment involved incubation of these cells for 180 minutes at 37°C in an assay buffer (1 ml) containing tracer concentrations of the radiolabeled ABC or AZT. Assay buffer containing radiolabeled drug was aspirated at the end of incubation period and the cells washed three times with 1 ml of ice-cold phosphate buffered saline. The cells were solubilized by adding 1 ml of 1% Triton X-100 (Sigma-Aldrich, Inc., Saint Louis, MO). Total protein concentration in each well was determined by the BCA™ protein assay kit (Pierce Biotechnology, Inc., Rockford, IL) and the corresponding radioactivity was determined by liquid scintillation counting (LS-6500, Beckman Coulter, Inc., Fullerton, CA). Tracer accumulation in the two cell variants was compared and the results were expressed as a percentage of control (total amount of radioactivity (DPM) accumulated per milligram of protein in the wild-type cell).
Directional transport
The wild-type and Bcrp1-transfected cells were seeded at a density of 2 x 10 5 per well and grown for 3 to 4 days on separate Transwell® permeable supports (Corning Inc., Corning, NY) until they formed a confluent Fresh drug-free assay buffer was placed on the receiver side. The assay plates were incubated on an orbital shaker (60 RPM) at 37°C for the entire duration of the experiment except while sampling. 200 µl samples were drawn from the receiver side at 0, 30, 60, and 90 minutes and replaced with fresh drug-free assay buffer. Similarly, 200 µl samples were drawn from the donor side at 0 and 180 minutes and replaced with the assay buffer containing radiolabeled nucleotides at the initial donor concentration. The amount of compound transported was calculated using the specific activities of the radiolabeled nucleotides (0.6Ci/mmol for ABC and 53mCi/mmol for AZT) and compared in the wild-type and transfected cells.
AZT and ABC directional transport experiments were also conducted in the presence of 50µM of unlabeled AZT or ABC to evaluate the saturability of [ 14 C] AZT and [ 3 H]-ABC transport.
Inhibitory effect of GF120913 and Ko143
Cellular accumulation experiments were conducted in the presence of inhibitors, where assay buffers containing GF120918 (5µM), Ko143 (200 nM) or probenecid (100µM) were used to pre-incubate the cells and for preparing solutions for the assay. The accumulation of ABC was determined at varying concentrations of GF120918 (0.3125, 0.625, 1.25, 2.5, 5.0 and 10µM) and Ko143 (0, 25, 50, 100, 125, 150, 175, 200 and 400nM) . The accumulation of AZT was determined at varying concentrations of GF120918 This article has not been copyedited and formatted. The final version may differ from this version. where effect is the fold increase in accumulation, seen in the presence of inhibitor, over the Bcrp1 control (without inhibitor). E0 is the cell accumulated DPM/mg protein in the Bcrp1 control, normalized to equal unity. Emax is the fold increase over Bcrp1 control at maximal inhibition, C is the concentration of the inhibitor in the incubating media, γ (gamma) is the shape factor (Hill coefficient) in the sigmoid model, and EC 50 is the concentration of inhibitor at half-maximal inhibition.
Directional transport assay by HPLC
The directional transport assay was also conducted using unlabeled ABC or AZT to confirm the transport of intact nucleoside. The assay was performed as described above using unlabelled ABC and AZT at a concentration of 5µM each. The samples were stored at -20ºC until analysis. For analysis 100µl samples were spiked with 5ng of AZT and AZdU as internal standards for ABC and AZT, respectively. Then 800µl of ethyl acetate was added and the sample vortexed vigorously for 10 minutes. The supernatant was dried under a flow of liquid nitrogen, reconstitued in 100µl of mobile phase and injected onto a HPLC system.
The analysis was performed on a Hypersil-BDS column (C-18, 2.1mm x 150mm, 5µM; Keystone Scientific, Inc.) maintained at 45ºC using a Shimadzu column oven (CTO-10Avp). The HPLC system consisted of a Shimadzu pump (LC-10ATvp), flow control valve (FCV-10ALvp), degasser (DGU-20A5), autoinjector (SIL-10ADvp), system controller (SCL-10Avp) and detector (SPD-10Avp). The flow rate of mobile phase (10mM ammonium phosphate buffer (pH 4.6) and methanol (80:20)) was set at 0.2 ml/min and UV absorbance was measured at 266nM.
Permeability calculations and efflux ratio
The effective directional permeabilities (P eff ) of the nucleosides were calculated from the permeability equation (equation 2) using slopes (dQ/dt) obtained in the initial linear range from the amount transported vs. time plots (for up to 90 minutes), where A is the area of the Transwell® membrane and Co is the initial donor conentration. The efflux ratio was determined as the ratio of the P eff calculated in the B-to-A direction divided by the P eff in the A-to-B direction.
Equation 2

Statistical analysis
Statistical analysis was performed using SigmaStat® 3.1 (SYSTAT Software, Inc.). Groups were compared using simple one-way ANOVA, and the Holm-Sidak method was used for the post hoc multiple comparison procedure with a significance level of p<0.05. 
Effect-Inhibitor Concentration Relationship: GF120918 and Ko143
Varying GF120918 and Ko143 concentrations were used to evaluate inhibitory effect on the Bcrp1- Response (inhibitory effect) was measured as the fold increase in accumulation observed in the presence of inhibitor when compared to the Bcrp1 cells without inhibitor (control). GF120918 exhibited a maximal response at 5µM with an Emax, EC50 and gamma of 4.1 ± 0.3 fold, 1.3 ± 0.3µM and 1.7 ± 0.5, respectively for ABC ( Figure 3A) , and 8 ± 0.5 fold, 0.31 ± 0.1µM and 0.75 ± 0.1, respectively for AZT ( Figure 3B ).
Ko143 exhibited a maximal response at 200nM with an Emax, EC50 and gamma of 7 ± 0.3 fold, 121 ± 5nM
This article has not been copyedited and formatted. The final version may differ from this version. and 6.1 ± 1.4, respectively for ABC ( Figure 3C ), and 6.7 ± 0.21 fold, 19.2 ± 1.5nM and 2.73 ± 0.7, respectively for AZT ( Figure 3D ). Figure 4C ). GF120918 and Ko143 significantly decreased this difference in directional flux of AZT in the Bcrp1-transfected cell lines ( Figure 6A and 6C). From these data, the P eff of AZT were calculated as described in the methods section. The efflux ratio of P eff in the Bcrp1-transfected cells was calculated to be approximately 11-fold greater than in the wild-type cells ( Figure 4D ). Both GF120918 and Ko143 could almost entirely reverse this difference in directional permeabilities in the two cell variants ( Figure 6B and 6D ).
BCRP-mediated Directional Flux of ABC and AZT
Both
Directional transport of intact nucleosides
Directional transport studies using unlabeled ABC and AZT measured by HPLC confirmed the transport of intact nucleosides in the tracer studies. For both unlabeled ABC and AZT the basolateral-to-apical flux was significantly higher and the apical-to-basolateral flux was lower in the Bcrp1-transfected cells when compared to the wild type ( Figure 7A and 7B). When plotted as a percentage of intial donor concentrations over time, there are similar profiles for both radiolabeled and unlabeled ABC and AZT (Figure 7A and 7B) and there was no difference in calculated permeabilities, indicating that for the expeimental time and system, the radiolabel was a good indicator of intact ABC and AZT transport.
Discussion
Numerous studies have reported the CNS distribution of ABC, AZT and other NRTIs to be low and it has been suggested that an active efflux transporter system is partially responsible for limiting CNS distribution of nucleosides (McDowell et al., 1999; Sawchuk and Yang, 1999; Thomas et al., 2001) . ABCG2/BCRP is a recently discovered member of the ATP-binding cassette family of transport proteins. This efflux transporter was discovered in mitoxantrone-resistant cell lines that do not over express P-gp or the MRPs (Doyle et al., 1998) . BCRP is localized in the plasma membrane of drug resistant tumor cells (Scheffer et al., 2000) and is found in barrier cells of various tissues like the small intestines, colon, bile canaliculi, placental syncytiotrophoblast (Maliepaard et al., 2001 ) and it has been recently described in the endothelial cells of the cerebral microvasculature (blood-brain barrier) (Cooray et al., 2002) . These cellular and tissue expression sites indicate that BCRP may be important in the absorption, distribution and elimination of its substrates. Moreover, recent studies have shown that human BCRP over-expressing cells showed a diminished intracellular accumulation and anti-HIV activity of the NRTIs AZT and 3TC (Wang et al., 2004) . The increased resistance of the BCRP over-expressing MT4 lymphocytes strongly suggested that the NRTI, AZT, is a substrate of human BCRP (Wang et al., 2004) , leading to ineffective intracellular concentrations of AZT and its active metabolites. Therefore, if AZT and other anti-HIV1 nucleosides prove to be avid substrates for BCRP-mediated transport, this efflux transporter could be important in limiting oral absorption, altering distribution to sites of efficacy and toxicity such as the CD4-positive lymphocytes, and finally, influencing blood-brain barrier penetration which would limit entry into important viral sanctuary sites such as the CNS.
This article has not been copyedited and formatted. The final version may differ from this version. In the current studies, we employed in vitro cell monolayers, both parental MDCKII cells and MDCKII cells transfected with Bcrp1 (Jonker et al., 2000) , cell types is mediated by Bcrp1 efflux, and strongly indicates that both ABC and AZT are substrates for Bcrp1. These data are the first reported evidence for the interaction of ABC with a specific efflux transporter or an active transporter of any type.
Given the strong evidence that ABC and AZT are Bcrp1 substrates, it was then useful to examine whether or not known inhibitors of NRTI active transport at critical sites can also inhibit Bcrp1. Probenecidsensitive CNS distribution of AZT was previously reported in the rat (Takasawa et al., 1997) , adult rhesus monkey (Cretton et al., 1991) and rabbit (Wong et al., 1993; Wang et al., 1997) . The influence of probenecid on efflux transport of other NRTIs, such as ddC, ddI and tenofovir (Takasawa et al., 1997; Gibbs and Thomas, 2002; Mallants et al., 2005) has also been reported. Therefore, we investigated the effect of probenecid on Bcrp1 transport to evaluate if the previously reported probenecid alterations of the CNS distribution of AZT and other NRTIs could be in part mediated through Bcrp1 efflux transport. Our results (Figure 2A and 2B) show that probenecid does not influence the Bcrp1-mediated transport of either ABC or AZT. This finding strongly suggests the previously reported effects of probenecid on the blood brain barrier permeability of AZT involves a transport system other than Bcrp1, such as organic anion transporters in the MRP subfamily or the OAT transport systems in the brain capillary endothelial cells (Sun et al., 2003) .
These cellular accumulation studies were followed by directional flux studies for ABC and AZT. permeabilities, for both ABC and AZT, show that, given the known orientation of Bcrp1 in the transfected MDCKII cells (Mohrmann et al., 2005) , there was the expected significant increase in the basolateral-toapical (B-to-A) transport over the apical-to-basolateral (A-to-B) transport in the Bcrp1 transfected cells, which was significantly higher than in the wild-type cells. This Bcrp1-mediated transport of either nucleoside was not saturated even in the presence of a high concentration (50µM of ABC and AZT) of unlabelled nucleoside (data not shown). These concentrations are approximately twenty-fold higher than normal therapeutic ABC and AZT concentrations in the plasma (Donnerer et al., 2003) .
The directional transport of ABC and AZT in the Bcrp1-transfected cells could be modulated using Bcrp1 inhibitors GF120918 and Ko143, and Ko143 was able to almost completely abolish this transport for both ABC and AZT ( Figure 5C and 6C). However, GF120918 was able to completely abolish Bcrp1-mediated transport of AZT but not ABC (Figure 5a and 6A). Concentration-dependent effects of these inhibitors on the accumulation of ABC and AZT in the transfected cells show that Ko143 is a more potent inhibitor for both ABC and AZT with an EC 50 of approximately 121 ± 5nM and 19.2 ± 1.5 nM, respectively, compared to approximately 1.32 ± 0.3µM and 0.31 ± 0.1 µM for GF120918 ( Figure 3A-D) . Hill coefficients (gamma values) were much larger for Ko143 than GF120918 for both ABC and AZT (6.1 vs 1.7, 2.73 vs 0.75, respectively) , which may imply the existence of cooperative inhibition. The mechanism of such an inhibition is unclear, and it is difficult to speculate based on model-fitted shape factors. However, it may be that Ko143 has a different binding site than GF120918 which is more sensitive to small changes in inhibitor concentration. More interestingly though, may be the possibility that Ko143 can exert its inhibitory effects through another mechanism that is not related to direct binding inhibition, but rather one that includes an intermediary signaling step which then lends itself to a switch-like behavior, triggered by a minimum concentration of Ko143. It is known that there is cooperativity in the inhibition of the p-glycoprotein (Wang, et al., 2000) . It is known that Bcrp1 transports as a homodimer or multimer, and as such could be subject to similar cooperative mechanisms of inhibition. However, it is not known whether other Bcrp1 substrates will give similar results as the two nucleosides under current study. Moreover, GF120918 did not completely inhibit the Bcrp-1 mediated accumulation of ABC. These results may explain the inability of GF120918 to be able to completely inhibit the difference in cellular accumulation and directional transport. Further studies are needed to evaluate the probable differences in mechanism of action, or binding sites, of these two inhibitors. The higher EC50
observed for ABC with both the inhibitors of Bcrp1 suggests that it may have a greater affinity for the efflux transporter compared to AZT.
Major obstacles for the successful treatment of HIV1 infection are the emergence of drug resistant strains and the failure of therapeutic agents, such as the NRTIs, to reach the so called viral sanctuary sites like the CNS (Sawchuk and Yang, 1999) . The eventual efficacy of anti-retroviral therapy therefore depends not only on reducing the number of viral particles in the blood, but also on the ability of these anti-HIV agents to reach viral reservoirs. P-glycoprotein (P-gp) and the multidrug-resistance associated proteins (MRPs) subfamily of multi-drug resistance proteins have been widely investigated for their influence on the disposition of a diverse array of therapeutic compounds. There is some suggested involvement of MRP4
and MRP5 and not P-gp in AZT efflux (Jorajuria et al., 2004 Our results conclusively show that the directional transport of ABC and AZT is mediated by the efflux transporter Bcrp1. BCRP mediated efflux may influence the oral bioavailability and possibly prevent the delivery of these important components of anti-retroviral therapy to the CNS, amniotic fluid and lymphocytes. These results suggest the need for further investigation to determine the in vivo contribution of BCRP in the oral bioavailability and disposition of ABC, AZT and other NRTIs used in therapy. Other components of ART, like the protease inhibitors, such as ritonavir, saquinavir and nelfinavir have been found to be effective inhibitors of this efflux transporter (Gupta et al., 2004) . Characterizing the role of BCRP in drug-drug interactions during the co-administration of BCRP substrates and/or inhibitors in combination therapy would be important follow-up studies for both the delivery of these NRTIs to target sites and may result in the altered efficacy or toxicity of NRTIs in AIDS therapy.
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